English | Español

Pharmaceuticals

+ Pharmaceuticals
Patient Daily | Aug 6, 2026

Early radionuclide therapy delays progression in metastatic prostate cancer, trial shows
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

Experts discuss emerging approaches for treatment-resistant depression on podcast episode
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

Ferroptosis-based therapy reviewed as potential treatment for advanced prostate cancer
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

American Lung Association announces 42nd Autumn Escape Bike Trek for September 2026 in Cape Cod
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

New review outlines biological mechanisms behind Ménière's disease and future research directions
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

Moderna receives FDA approval for mRNA-based flu vaccine mFLUVISA
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

University of Oklahoma researcher receives grant to study cholesterol in pancreatic cancer survival
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

BioVie shares fall after unclear results from Parkinson’s disease trial

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'